$MYNZ Key Corporate & Product Development Highligh
Post# of 46498
(Total Views: 226)
Posted On: 09/27/2022 12:57:36 PM
$MYNZ Key Corporate & Product Development Highlights
Accelerated international commercial activities for ColoAlert, the Company’s highly efficacious and easy-to-use detection test for colorectal cancer (CRC)
Appointed Darin Leigh, former Abbott and Luminex executive, as Chief Commercial Officer
Established partnership with Dante Labs to market ColoAlert in Italy and the United Arab Emirates
Initiated and enrolled the first patient in an international clinical study (ColoFuture) evaluating the integration of novel mRNA biomarkers into ColoAlert – potentially upgrading its technical profile to achieve “gold standard” status for CRC at-home testing
Received supportive feedback from the U.S. Food and Drug Administration (FDA) on ColoAlert’s pre-submission package for its U.S. pivotal clinical trial set to commence in Q4 2022
Achieved multiple preclinical milestones supporting the continued development of PancAlert, a potential first-in-class screening test for pancreatic cancer
Executed a $25.8 million (gross) public follow-on offering
Expanded Strategic Advisory Board of global leaders in molecular diagnostic development and commercialization
Accelerated international commercial activities for ColoAlert, the Company’s highly efficacious and easy-to-use detection test for colorectal cancer (CRC)
Appointed Darin Leigh, former Abbott and Luminex executive, as Chief Commercial Officer
Established partnership with Dante Labs to market ColoAlert in Italy and the United Arab Emirates
Initiated and enrolled the first patient in an international clinical study (ColoFuture) evaluating the integration of novel mRNA biomarkers into ColoAlert – potentially upgrading its technical profile to achieve “gold standard” status for CRC at-home testing
Received supportive feedback from the U.S. Food and Drug Administration (FDA) on ColoAlert’s pre-submission package for its U.S. pivotal clinical trial set to commence in Q4 2022
Achieved multiple preclinical milestones supporting the continued development of PancAlert, a potential first-in-class screening test for pancreatic cancer
Executed a $25.8 million (gross) public follow-on offering
Expanded Strategic Advisory Board of global leaders in molecular diagnostic development and commercialization
(0)
(0)Scroll down for more posts ▼